A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter

Yen Chuan Ou, Thomas Gardner, Chinghai Kao, Haiyen E. Zhau, Leland W. Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The expression of the MN/carbonic anhydrase IX (CA IX) protein is detected in renal cell carcinoma (RCC). A tumor-specific MN promoter was designed and evaluated. Materials and Methods: Western blot, reverse transcription-PCR and Northern blot for MN expression were performed on Hela cells, LNCaP and four human RCC cell lines. The MN promoter (554 bp) was cloned into pGL3 luciferase reporter vectors and their activities were tested. Results: Hela cells, SKRC-31 and SKRC-38 expressed high levels of MN RNA and MN protein. The MN promoter has 5- to 10-fold higher activity in MN-positive cell lines than in MN-negative cell lines. It could enhance the activity of the basic SV40 early promoter (6 to 25 fold) in MN-positive cells but not in MN-negative cells. Conclusion: MN expression in RCC may derive from altered expression of transcriptional factor(s), which binds to the MN enhancer element, and can be used for tumor specific toxic gene therapy for RCC.

Original languageEnglish
Pages (from-to)881-886
Number of pages6
JournalAnticancer Research
Volume25
Issue number2 A
StatePublished - Mar 2005

Fingerprint

Renal Cell Carcinoma
Genetic Therapy
HeLa Cells
Cell Line
Poisons
Luciferases
Northern Blotting
Reverse Transcription
Neoplasms
Proteins
Western Blotting
RNA
Polymerase Chain Reaction
Carbonic Anhydrase IX

Keywords

  • Carbonic anhydrase IX (CA IX)
  • Gene therapy
  • MN protein
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter. / Ou, Yen Chuan; Gardner, Thomas; Kao, Chinghai; Zhau, Haiyen E.; Chung, Leland W.

In: Anticancer Research, Vol. 25, No. 2 A, 03.2005, p. 881-886.

Research output: Contribution to journalArticle

@article{6afd9bbade884343ae57574c1c329117,
title = "A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter",
abstract = "Background: The expression of the MN/carbonic anhydrase IX (CA IX) protein is detected in renal cell carcinoma (RCC). A tumor-specific MN promoter was designed and evaluated. Materials and Methods: Western blot, reverse transcription-PCR and Northern blot for MN expression were performed on Hela cells, LNCaP and four human RCC cell lines. The MN promoter (554 bp) was cloned into pGL3 luciferase reporter vectors and their activities were tested. Results: Hela cells, SKRC-31 and SKRC-38 expressed high levels of MN RNA and MN protein. The MN promoter has 5- to 10-fold higher activity in MN-positive cell lines than in MN-negative cell lines. It could enhance the activity of the basic SV40 early promoter (6 to 25 fold) in MN-positive cells but not in MN-negative cells. Conclusion: MN expression in RCC may derive from altered expression of transcriptional factor(s), which binds to the MN enhancer element, and can be used for tumor specific toxic gene therapy for RCC.",
keywords = "Carbonic anhydrase IX (CA IX), Gene therapy, MN protein, Renal cell carcinoma",
author = "Ou, {Yen Chuan} and Thomas Gardner and Chinghai Kao and Zhau, {Haiyen E.} and Chung, {Leland W.}",
year = "2005",
month = "3",
language = "English",
volume = "25",
pages = "881--886",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter

AU - Ou, Yen Chuan

AU - Gardner, Thomas

AU - Kao, Chinghai

AU - Zhau, Haiyen E.

AU - Chung, Leland W.

PY - 2005/3

Y1 - 2005/3

N2 - Background: The expression of the MN/carbonic anhydrase IX (CA IX) protein is detected in renal cell carcinoma (RCC). A tumor-specific MN promoter was designed and evaluated. Materials and Methods: Western blot, reverse transcription-PCR and Northern blot for MN expression were performed on Hela cells, LNCaP and four human RCC cell lines. The MN promoter (554 bp) was cloned into pGL3 luciferase reporter vectors and their activities were tested. Results: Hela cells, SKRC-31 and SKRC-38 expressed high levels of MN RNA and MN protein. The MN promoter has 5- to 10-fold higher activity in MN-positive cell lines than in MN-negative cell lines. It could enhance the activity of the basic SV40 early promoter (6 to 25 fold) in MN-positive cells but not in MN-negative cells. Conclusion: MN expression in RCC may derive from altered expression of transcriptional factor(s), which binds to the MN enhancer element, and can be used for tumor specific toxic gene therapy for RCC.

AB - Background: The expression of the MN/carbonic anhydrase IX (CA IX) protein is detected in renal cell carcinoma (RCC). A tumor-specific MN promoter was designed and evaluated. Materials and Methods: Western blot, reverse transcription-PCR and Northern blot for MN expression were performed on Hela cells, LNCaP and four human RCC cell lines. The MN promoter (554 bp) was cloned into pGL3 luciferase reporter vectors and their activities were tested. Results: Hela cells, SKRC-31 and SKRC-38 expressed high levels of MN RNA and MN protein. The MN promoter has 5- to 10-fold higher activity in MN-positive cell lines than in MN-negative cell lines. It could enhance the activity of the basic SV40 early promoter (6 to 25 fold) in MN-positive cells but not in MN-negative cells. Conclusion: MN expression in RCC may derive from altered expression of transcriptional factor(s), which binds to the MN enhancer element, and can be used for tumor specific toxic gene therapy for RCC.

KW - Carbonic anhydrase IX (CA IX)

KW - Gene therapy

KW - MN protein

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=17444376451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444376451&partnerID=8YFLogxK

M3 - Article

C2 - 15868923

AN - SCOPUS:17444376451

VL - 25

SP - 881

EP - 886

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -